The closing price of Biodesix Inc (NASDAQ: BDSX) was $1.40 for the day, down -7.28% from the previous closing price of $1.51. In other words, the price has decreased by -$0.1100 from its previous closing price. On the day, 2317434 shares were traded.
Ratios:
Our analysis of BDSX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.15 and its Current Ratio is at 1.19. In the meantime, Its Debt-to-Equity ratio is 13.25 whereas as Long-Term Debt/Eq ratio is at 13.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Morgan Stanley on November 17, 2021, Downgraded its rating to Equal-Weight and sets its target price to $11 from $21 previously.
On November 23, 2020, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $20.Morgan Stanley initiated its Overweight rating on November 23, 2020, with a $20 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 12 ’24 when Hutton Scott sold 29,708 shares for $1.66 per share. The transaction valued at 49,455 led to the insider holds 465,011 shares of the business.
Cowie Robin Harper sold 8,699 shares of BDSX for $14,481 on Feb 12 ’24. The CFO, Sec’y & Treasurer now owns 169,410 shares after completing the transaction at $1.66 per share. On Feb 12 ’24, another insider, O’Kane Kieran, who serves as the Chief Commercial Officer of the company, sold 5,412 shares for $1.66 each. As a result, the insider received 9,009 and left with 68,005 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BDSX now has a Market Capitalization of 133.78M and an Enterprise Value of 168.19M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.76 while its Price-to-Book (P/B) ratio in mrq is 29.42. Its current Enterprise Value per Revenue stands at 3.43 whereas that against EBITDA is -4.53.
Stock Price History:
Over the past 52 weeks, BDSX has reached a high of $2.21, while it has fallen to a 52-week low of $1.03. The 50-Day Moving Average of the stock is 1.6129, while the 200-Day Moving Average is calculated to be 1.5379.
Shares Statistics:
BDSX traded an average of 106.99K shares per day over the past three months and 286.16k shares per day over the past ten days. A total of 96.24M shares are outstanding, with a floating share count of 24.79M. Insiders hold about 74.28% of the company’s shares, while institutions hold 16.09% stake in the company. Shares short for BDSX as of Mar 15, 2024 were 181.14k with a Short Ratio of 1.69, compared to 170.09k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.19% and a Short% of Float of 0.37%.
Earnings Estimates
The firm’s stock currently is rated by 2 analysts. On average, analysts expect EPS of -$0.15 for the current quarter, with a high estimate of -$0.15 and a low estimate of -$0.15, while EPS last year was -$0.24. The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.1 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.41 and -$0.44 for the fiscal current year, implying an average EPS of -$0.42. EPS for the following year is -$0.32, with 2 analysts recommending between -$0.27 and -$0.38.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 2 analysts. It ranges from a high estimate of $14.3M to a low estimate of $14M. As of the current estimate, Biodesix Inc’s year-ago sales were $9.06M, an estimated increase of 56.30% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $15.7M, an increase of 32.20% less than the figure of $56.30% in the same quarter last year. There is a high estimate of $15.7M for the next quarter, whereas the lowest estimate is $15.7M.
A total of 2 analysts have provided revenue estimates for BDSX’s current fiscal year. The highest revenue estimate was $65.5M, while the lowest revenue estimate was $65M, resulting in an average revenue estimate of $65.25M. In the same quarter a year ago, actual revenue was $49.09M, up 32.90% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $79.04M in the next fiscal year. The high estimate is $82.5M and the low estimate is $75.58M. The average revenue growth estimate for next year is up 21.10% from the average revenue estimate for this year.
